GeneReach Biotechnology Corp.
4171
Rank in Stocks
#25430
GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes... GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes in the development, production, and commercialization of advanced nucleic acid detection technologies. The company's extensive product line features essential laboratory instrumentation, including automated nucleic acid extraction systems, prep homogenization systems, and mini centrifuges. GeneReach also provides a wide range of reagents and consumables, such as human In Vitro Diagnostic (IVD) assays, specific iiPCR reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and various research-grade reagents and supplies. Beyond its product offerings, GeneReach delivers comprehensive services. These encompass polymerase chain reaction (PCR) training programs, expert molecular diagnostic technical solutions, laboratory installation assistance, OEM/ODM contract manufacturing capabilities, and collaborative research services. Its innovative solutions cater to a diverse clientele, with applications spanning aquaculture, agriculture, food safety, human health, and the welfare of companion animals and livestock. GeneReach Biotechnology Corp. was established in 2004.
Share Price
$0.45726688
Last synced: 2026-11-10
Market Cap
$26.00M
Change (1 day)
-0.99%
Change (1 year)
-35.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GeneReach Biotechnology Corp. (4171)
Category
Healthcare
EPS for GeneReach Biotechnology Corp. (4171)
EPS as of June 2026 TTM: $-0.02
According to GeneReach Biotechnology Corp.'s latest financial reports, its current EPS (TTM) is $-0.02. At the end of 2025 the company had an EPS of $-0.06, equal to its 2024 EPS of $-0.06.
EPS history for GeneReach Biotechnology Corp. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.02 | -60.83% |
| 2025 | $-0.06 | -3.00% |
| 2024 | $-0.06 | -32.70% |
| 2023 | $-0.09 | -175.00% |
| 2022 | $0.13 | -46.85% |
| 2021 | $0.24 | 48.15% |
| 2020 | $0.16 | 238.64% |
| 2019 | $0.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -66,738.30% |
US
|
|
| $-7.07 | 29,985.11% |
US
|
|
| $-5.29 | 22,410.64% |
AU
|
|
| $12.88 | -54,908.94% |
BE
|
|
| $21.56 | -91,844.68% |
NL
|
Questions about GeneReach Biotechnology Corp.'s earnings per share (EPS)
What is GeneReach Biotechnology Corp.'s earnings per share (EPS)?
GeneReach Biotechnology Corp.'s earnings per share (EPS) over the last twelve months is $-0.02, as of Jun 2026.
What was GeneReach Biotechnology Corp.'s earnings per share (EPS) in 2025?
In 2025, GeneReach Biotechnology Corp.'s earnings per share (EPS) was $-0.06, compared with $-0.06 in 2024.
How has GeneReach Biotechnology Corp.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, GeneReach Biotechnology Corp.'s earnings per share (EPS) was highest in 2021 ($0.24) and lowest in 2023 ($-0.09).
How does GeneReach Biotechnology Corp.'s earnings per share (EPS) compare with similar companies?
GeneReach Biotechnology Corp.'s earnings per share (EPS) ($-0.02) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.